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ABSTRACT
Background: Congenital cytomegalovirus (CMV) infection is the most common non-genetic 
cause of sensorineural hearing loss (SHNL) in children. Only about 10% to 15% of children 
with congenital CMV are symptomatic, and most are not diagnosed at birth. About 7% to 
15% of clinically asymptomatic patients may develop later complications, including SNHL, 
which is the most common sequela in clinically asymptomatic patients. In this study, hearing 
status was investigated in children with confirmed CMV infection and neonatal hearing 
screening (NHS) histories were reviewed to explore hearing loss caused by CMV.
Methods: The medical records of 58 children who were diagnosed with confirmed CMV 
infection were reviewed for clinical symptoms and signs of CMV infection. Hearing status 
was evaluated with age-appropriate audiological test batteries.
Results: A total of 58 children (M:F = 32:26 patients; age at study: mean, 5.62 years, 
range, 1-10 years) were diagnosed serologically with CMV infection (14 patients, 21.1%), or 
diagnosed via PCR of serum (5, 7.9%) and/or PCR from urine (19, 26.8%). Hearing loss was 
confirmed in 11 children (19.0%), being bilateral in 6 (54.5%), and unilateral in 5 (45.5%). 
Note that 7 of 17 ears with hearing loss passed NHS and were diagnosed only after re-
evaluation when CMV infection was identified.
Conclusion: Hearing loss is a serious complication of CMV infection in children. Our 
results highlight the importance of timely audiological evaluation in children with clinically 
symptomatic CMV infection even if they pass NHS.
Keywords: Hearing Loss; Cytomegalovirus; Newborn Screening
INTRODUCTION
Congenital cytomegalovirus (CMV) infection is the most common intrauterine infection in 
humans. The average prevalence at birth has been estimated as about 0.7%.1,2 CMV infection 
in utero causes children to be born with or develop many abnormalities, including petechiae, 
pneumonitis, hepatosplenomegaly, microcephaly, and chorioretinitis.3 In addition, many 
patients with congenital CMV suffer from neurological deficits, including hearing loss and 
vision loss, and developmental delays. At birth, only a small portion (10%–15%) of children 
with congenital CMV are symptomatic, and the majority are asymptomatic. The prevalence 
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of hearing loss is 30% to 65% in symptomatic neonates and 7%–15% in asymptomatic 
neonates.4-7 Congenital CMV infection is the most common non-genetic cause of congenital 
sensorineural hearing loss (SNHL).8 Timely diagnosis and intervention are essential for 
children with SNHL to prevent delayed language development; thus, universal newborn 
hearing screening (NHS) programs have been implemented in many countries (including 
Korea) to identify children at high risk for congenital SNHL. However, a significant portion 
of children with moderate or severe bilateral hearing loss may remain undiagnosed.9 
In addition, children with progressive or fluctuating hearing loss may pass the NHS 
performed shortly after birth. Hearing loss associated with CMV infection is known to be 
primarily SNHL, although conductive and mixed-type hearing loss may also be present.10 
The presentation of hearing loss in those with CMV infection varies; loss may be mild to 
profound, and the hearing threshold may change over time.11 Hearing loss may be present 
at birth or develop later; fluctuation/progression of hearing loss has been reported.12-14 As 
hearing loss may not be evident at birth, children with CMV infection may pass NHS. Thus, 
long-term follow-up of hearing is essential in those with confirmed CMV infection.6,15,16
The incidence of congenital CMV infection depends on the population CMV seroprevalence.8 
In Korea, the maternal seroprevalence of CMV IgG may be as high as 98.1%, which indicates 
that risk for congenital CMV infection may be of concern.17 However, little Korean data are 
available. One study reported an incidence of congenital CMV infection of 1.2% in a small 
population of Korean children.18 Another study found that CMV was a significant cause of 
SNHL in a selected population of neonates and infants.19 Although recent studies support 
the suggestion that additional targeted or universal CMV screening (in addition to NHS) 
would improve the detection of children at risk for hearing loss caused by CMV infection,20,21 
such screening has yet been widely implemented in Korea. One recent study reported that 
targeted CMV screening in infants who did not pass the NHS were diagnosed with congenital 
CMV infection.22 Here, we performed a retrospective review of children with confirmed CMV 
infection, including congenital CMV infection, to describe their hearing status and describe 
their NHS results to provide basic information relevant to future implementation of CMV 
screening programs.
METHODS
We retrospectively evaluated the medical records of 58 children in whom CMV infection was 
confirmed before the age of 1 year and had undergone diagnostic audiological evaluations 
between March 2008 and December 2018 at Gangnam Severance Hospital, Yonsei University 
College of Medicine. The CMV infection was diagnosed using real-time PCR assay of either 
serum or urine specimen for viral DNA in all infants. Clinical confirmation of congenital 
CMV infection was made when CMV infection was confirmed during the first 2 weeks of life. 
All perinatal histories were reviewed for clinical symptoms and signs of CMV infection. Our 
hospital utilizes a two-staged NHS program using automated auditory brainstem response 
(AABR), but CMV testing is not routinely performed. AABR was performed using 35 dB HL 
click stimuli with an ALGO III AABR system (Natus Medical Inc., San Carlos, CA, USA). 
Infants who did not pass both steps of screening, in either or both ears, were referred for 
diagnostic audiological evaluation in our ENT department. Usual schedule for diagnostic 
audiologic evaluations were at 1 month and follow-up at 3 and 6 months if needed. At the 
time of the study, CMV testing was not routinely recommended for infants who did not pass 
the NHS. When infants who did not pass NHS were referred, we evaluated hearing status 
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using age-appropriate audiological test batteries, including auditory brainstem response 
(ABR), auditory steady-state response (ASSR) and transiently evoked otoacoustic emission 
(TEOAE). All tests were performed in a double-walled soundproof booth in accordance 
with ANSI standard S3.1-1999 (R 2008). ABRs were evaluated using the GSI Audera® AEP 
system running dedicated software (Grason-Stadler, Eden Prairie, MN, USA). Disposable 
electrodes (Nicolet Biomedical, Madison, WI, USA) were placed on the high forehead and 
on the ipsilateral and contralateral mastoids. All electrodes had impedances < 2kΩ. Stimuli 
(50-µs clicks at 90 dB peak equivalent sound pressure level [peSPL]) were presented via the 
Telephonics TDH 49 headphones at a rate of 11 clicks/s, with alternating polarity. The signals 
were bandpass-filtered (100–1,500 Hz) and averaged over at least 8,000 repetitions. The 
amplitudes of waves I and V were measured from the peak to the following troughs. ASSR 
was recorded using GSI Audera system (Grason-Stadler, Madison, MI, USA) Electrode discs 
of Ag/AgCl were fixed with electrolytic paste at Cz, Fz and ear lobe. TEOAEs were recorded 
using ILO 92 Otodynam- ics analyzer system (Otodynamics, England, UK) and ILO V6 
software. A click stimulus with 80 μs duration was presented at a repetition interval of 20 
msec. TEOAEs were considered present (“pass”) if the signal-to-noise ratio was 6 dB or great 
in at least 3 of 5 frequency bands, and absent (“refer”) otherwise. Hearing was categorized 
as normal (0–25 dB) or with mild (26–40 dB), moderate (41–55 dB), moderate to severe 
(56–70 dB), severe (71–90 dB), or profound (≥ 91dB) hearing loss according to ISO 1964 as in 
previous studies.4,19 We graded hearing status using the hearing threshold of the better ear. 
Asymmetrical hearing loss was defined as more than 15 dB difference in hearing thresholds 
in both ears. Deterioration or improvement in hearing was defined as a change of ≥ 10 dB in 
the hearing threshold. Descriptive analyses were performed using SPSS for Windows ver. 12.0 
(IBM, Chicago, IL, USA). All data are presented as means ± standard deviations.
Ethics statement
This study was approved by the Institutional Review Board (IRB) of Yonsei University College 
of Medicine Gangnam Severance Hospital (IRB No. 3-2019-0220). The IRB approved the 
conduction of this study without the informed consent from the participants because this 
study used anonymized retrospective EMR data.
RESULTS
A total of 58 children (M:F = 32:26; age at study: mean, 94 months, range, 40-143 months) 
were included. CMV infection was diagnosed serologically (IgM, 14 patients, 21.1%) or 
by PCR of serum (5, 7.9%) and/or urine (19, 26.8%). CMV infection was diagnosed before 
6 months of age in most patients (46 patients, 79.3%) (Fig. 1). Among the 18 patients 
(31.0%) who were diagnosed before 1 month of age, 6 patients were diagnosed within the 
first 2 weeks as congenital CMV infection. CMV screening is not yet part of the universal 
neonatal screening; the reasons for CMV screening include maternal CMV seroconversion 
or abnormalities evident on physical examinations or neurosonography. The clinical 
manifestation of CMV infection were reviewed; 16 patients (27.6%) were asymptomatic, and 
35 (60.3%) were symptomatic, and medical records were inadequate in 5 patients (8.6%) 
(Table 1). Clinical symptoms and signs included hepatitis (62.9%), hyperbilirubinemia 
(28.6%), pneumonia (14.3%), and hepatic splenomegaly (5.7%), and chorioretinitis (2.9%).
Children were referred for diagnostic audiological evaluation when CMV infection was 
confirmed, but the tests were performed later in some children (when the general condition 
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stabilized). Hearing thresholds were estimated from click-evoked ABR and/or ASSR 
measurements. The mean age at the diagnosis of hearing loss was 2.27 ± 3.52 months (range, 
0.25–12 months) (Fig. 2). Six patients were diagnosed with hearing loss before CMV infection 
was confirmed. Five were diagnosed with CMV infection and repeat audiological evaluations 
then confirmed hearing loss.
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Age at diagnosis of CMV infection
0–2 wk 1–3 mon 6 mon–1 yr2 wk–1 mon 3–6 mon
Fig. 1. Age at confirmation of CMV infection (n = 58). The figure shows distribution of patients who were confirmed 
of CMV infection at each age group, including 6 patients with congenital CMV infection confirmed within the first 
2 weeks after birth. 
CMV = cytomegalovirus.
Table 1. Clinical manifestations in 58 children with confirmed congenital cytomegalovirus infection
Group Symptoms Values





Asymptomatic (n = 16, 27.6%)
Unclear (n = 7, 12.1%)
Values are presented as number (%).




























Age of CMV infection diagnosis (mon)
Age of HL detection (mon)
Fig. 2. Age at detection of HL and diagnosis of CMV infection (n = 11). Most patients were diagnosed with CMV 
infection before hearing loss was confirmed. 
HL = hearing loss, CMV = cytomegalovirus.
Hearing loss was diagnosed in 11 patients (19.0%), being bilateral in 6 (54.5%) (Table 2). 
Hearing loss was mild in one patient, moderate in two, moderate to severe in one, and 
severe in two. The NHS results of all children were reviewed (Table 3). Seven of the 17 ears 
(41.2%) with confirmed hearing loss and CMV infection had passed NHS. The hearing status 
of these ears varied, ranging from normal to profound in terms of hearing loss. The clinical 
characteristics and hearing status of the 11 patients are listed in Table 4. Seven patients 
(63.6%) were admitted to NICU for 28.4 ± 25.7 days (range, 13 to 90 days). Brain imaging 
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Table 2. Hearing status of children with HL and confirmed congenital cytomegalovirus infection (n = 11)
Patients (n = 11) Values
Unilateral HL 5 (45.5)
Bilateral HL 6 (54.5)
Hearing status of the better ear
Normal 5 (50.0)
Mild HL 1 (9.1)
Moderate HL 2 (18.2)
Moderate to severe HL 1 (9.1)
Severe HL 2 (18.2)
Profound HL 0 (0.0)
Values are presented as number (%).
HL = hearing loss.
Table 3. Hearing status and NHS results of the ears (n = 22) of children with HL
Hearing status Total Passed NHS Failed NHS
Ears (n = 22)
Normal 5 (22.7) 3 (60.0) 2 (40.0)
HL 17 (77.3) 7 (41.2) 10 (58.8)
Ears with HL (n = 17)
Mild HL 4 (23.5) 2 (50.0) 2 (50.0)
Moderate HL 2 (11.8) 0 (0.0) 2 (100.0)
Moderate to severe HL 5 (29.4) 1 (20.0) 4 (80.0)
Severe HL 1 (5.9) 1 (100.0) 0 (0.0)
Profound HL 5 (29.4) 3 (60.0) 2 (40.0)
Values are presented as number (%).
NHS = neonatal hearing screening, HL = hearing loss.
Table 4. Clinical characteristics of children with confirmed congenital cytomegalovirus infection and HL (n = 11)
Patient  
No.
Sex Laterality Initial hearing threshold,  
right/left, dB




NICU stay,  
day
Neuroimaging
#2 F Bilateral, 
symmetrical
NR/80 - - Pass/Pass 90 Brain CT: wnl
#12 F Bilateral, 
symmetrical
60/50 Stable 14 Refer/Refer 20 Brain CT: wnl
#24 M Unilateral 50/40 Fluctuating  
(range, 30–50 dB)
6 Pass/Pass - Brain CT: wnl
#29 F Bilateral, 
asymmetrical
NR/50 Stable 3 Refer/Refer 16 Brain MRI: polymicrogyria,  
cortical dysplasia
#38 F Bilateral, 
symmetrical
70/60 Stable 2 Refer/Refer - Brain MRI: CSF space widening
#41 F Bilateral, 
asymmetrical
40/60 - - Pass/Pass - Brain MRI: microphthalmia,  
CSF space widening
#45 M Unilateral 80/25 Improving  
(40/25 after 8 mon)
8 Refer/Refer 28 Neurosonography: wnl
#48 M Unilateral 40/25 Stable 3 Refer/Refer 11 Brain CT: wnl
#51 M Unilateral 25/NR Stable 8 Pass/Pass - Neurosonography: wnl
#52 F Unilateral 20/NR Stable 14 Pass/Pass 21 Brain CT: wnl
#74 F Bilateral, 
asymmetrical
NR/50 - - Refer/Refer 13 Brain MRI: polymicrogyria
HL = hearing loss, NHS = neonatal hearing screening, NICU = neonatal intensive care unit, CT = computed tomography, MRI = magnetic resonance imaging.
studies showed abnormalities in 5 patients (45.5%), but abnormalities in the inner ear 
structures were not identified. Follow-up audiologic tests were performed in 8 patients; most 
evidenced no change in hearing status. One patient exhibited fluctuation of hearing in both 
ears; another showed improved hearing in one ear.
DISCUSSION
We investigated how children with hearing loss related to CMV infection were initially 
diagnosed and to highlight here the importance of audiological evaluation of such children. 
In our hospital, all neonates undergo NHS, but CMV screening tests are not routinely 
performed. Children are recommended for such tests only if there is a clinical suspicion of 
perinatal CMV infection or when maternal CMV infection is clinically suspected or diagnosed. 
Our pediatricians and otologists in our hospital agree that formal, diagnostic audiological 
evaluation is appropriate if CMV infection is confirmed via PCR of urine or serum samples, 
even if children initially pass NHS. Overall, 11/58 patients (19.0%) with confirmed CMV 
infection were diagnosed with hearing loss; this incidence is less than that in a study of Korean 
children (hearing loss was present in 33.3% of those with congenital CMV infection in that 
study).19 Several factors may explain this difference. Our patients had confirmed with CMV 
infection within 1 year of birth, but only 6 patients were diagnosed with congenital CMV 
infection, which must be confirmed within the first 2 weeks of life. It is noteworthy that 5 of 6 
patients (83.3%) with congenital CMV infection were also diagnosed with hearing loss, while 
hearing loss was less frequent in patients later diagnosed with CMV infection (6/52 patients, 
11.5%). In contrast, Kim et al. investigated children diagnosed with congenital CMV. It is not 
possible to directly compare the frequency of hearing loss in that study to that in our present 
work. In addition, in our work, initial clinical suspicion of CMV infection was followed by a 
delay prior to laboratory confirmation of CMV infection. This was considered inappropriate, 
and we have revised (improved) our CMV testing protocol as a result. Kim et al.'s study19 
included three distinct groups of children: those diagnosed clinically with congenital CMV, 
those recruited from neonatal intensive care units (NICU), and SNHL patients with confirmed 
congenital CMV infection who underwent cochlear implantation. As Kim et al.22 noted, NICU 
patients more commonly arrive preterm than other infants, and their prevalence of hearing loss 
may not reflect that of the general infant population. Our retrospective study enrolled children 
with confirmed CMV infection; these are also not representative of the general population. 
However, both studies support the suggestion that it is important to evaluate the hearing of 
children with CMV infection. Another study reported that when the newborns who did not pass 
NHS were screened for CMV, 1.5% of them were positive, and 0.8% of the newborns who did 
not pass NHS were diagnosed with asymptomatic congenital CMV infection, highlighting the 
potential advantage of timely CMV screening. With increased attention to early identification 
and treatment of congenital CMV infection, two approaches for CMV screening in newborns 
have been proposed. While the diagnostic benefits of universal screening of congenital CMV 
infection in all newborns are undebatable, targeted CMV screening of newborns who do not 
pass NHS has been adopted in some hospitals and locations.5,22,23 However, targeted screening 
of CMV inevitably will miss cases of delayed onset hearing loss in patients with congenital CMV 
infection. A recent study suggested that addition of genetic and CMV screening to preexisting 
NHS programs would help identify newborns with increased risk of hearing loss due to 
congenital CMV infection.21 Our data also shows that passing the NHS does not necessarily rule 
out hearing loss in CMV infection, especially congenital CMV infected infants, supporting the 
benefit of universal CMV screening in all newborns.
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Of the various causes of congenital SNHL, CMV infection is worthy of clinical attention 
because antiviral medications are available. We could not determine the effect of treatment 
of CMV infection on hearing loss because follow-up hearing evaluation was not performed 
in the two patients with ganciclovir treatment (case no. #41, 74). In one study, treatment of 
symptomatic congenital CMV children with ganciclovir prevented hearing loss (compared 
to a control group).24 Oral valganciclovir improved hearing and language outcomes.25 
In another study that treated symptomatic congenital CMV infection with valganciclovir 
for 6 months, hearing was improved in the long term compared to a group with 6 weeks 
of therapy.26 However, a recent study of 16 patients treated with valganciclovir revealed a 
measurable, but not a statistically significant, decline in hearing.27 Thus, hearing outcomes 
vary among studies; and the antiviral data were all obtained from patients with symptomatic 
CMV infection. Further long-term studies featuring comprehensive audiological evaluation 
and long-term follow-ups are needed to better understand the benefits and risks of antiviral 
therapies in terms of hearing loss. However, it is clear that patients with CMV and SNHL 
require particular attention. The universal NHS program is available through the Korean 
National Health Insurance Service in Korea and plays an invaluable role in terms of early 
identification of, and intervention for, hearing loss. However, the NHS protocol may not 
identify children with progressive hearing loss (who pass initial NHS testing but later 
develop hearing loss), or children with fluctuating hearing thresholds (which is possible in 
hearing loss related to CMV infection). We found that passing the NHS did not necessarily 
guarantee later normal hearing, particular for patients with confirmed CMV infection. 
Clinicians treating such children should be aware that, even if the children have passed 
NHS, a diagnostic audiologic evaluation is appropriate. Regular follow-up hearing tests 
are recommended to ensure that progressive/fluctuating hearing loss is detected. In Korea, 
routine hearing screening is universally available in the first year of elementary school. Prior 
to that time, we recommend yearly hearing follow-up in the hospital.
This descriptive study is an initial attempt to emphasize the importance of audiological 
evaluation of children with CMV infection and the need for interspecialty consultation 
to identify hearing loss in a timely manner. A strength of our study is that we performed 
diagnostic audiological tests; we did not rely on the hearing screen to identify hearing 
loss. Limitations of the study include the retrospective nature of the work and the relatively 
small number of patients enrolled; a bias toward including more severely affected patients 
may have been in play. In addition, the timing of audiological evaluations was varied, and 
only a few patients underwent such evaluations. Another limitation involves the lack of 
neurodevelopmental data. Apart from the risk of delayed language development attributable 
to hearing loss, neurodevelopment should be regularly checked, in particular in symptomatic 
patients. Further studies are needed to define the progression of hearing loss in patients 
with CMV infection and the possible therapeutic utility of antivirals in terms of long-term 
improvement or stabilization of hearing. Regular follow-up of audiological evaluation is 
essential for children with confirmed CMV infection.
Hearing loss is an important manifestation of both symptomatic and asymptomatic CMV 
infection. Our data are in line with reports that indicate that hearing loss is associated with 
confirmed CMV infection and show that the NHS program inadequately identifies such loss. 
Our results support the suggestion that more comprehensive screening for CMV-related 
hearing loss is required in Korea.
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